Tech Company Financing Transactions
NADMED Funding Round
On 8/22/2024, NADMED raised $4 million in Series A funding from Business Finland and Voima Ventures.
Transaction Overview
Company Name
Announced On
8/22/2024
Transaction Type
Venture Equity
Amount
$4,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to expand operations and its development efforts.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
c/o Terkko Health Hub, Haartmaninkatu 4, Building 14
Helsinki, 00290
Finland
Helsinki, 00290
Finland
Phone
Website
Email Address
Overview
After years of study and development, NADMED brings to market a reliable yet simple technology for extracting and measuring all four NADs and two glutathiones. The technology is based on an accurate colorimetric quantification that can be performed even from a minuscule amount of blood. The NADMED method's key advantage is that it can measure metabolites individually, unlike any other method. The NADMED method is based on solid scientific research from the University of Helsinki.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jari Närhi
Chief Marketing Officer
Kai Herdin
Chief Operating Officer
Jana Buzkova
Chief Scientific Officer
Liliya Euro
VP - Bus. Development
Joonas Vaahtera
VP - Regulatory Affairs
Riikka Äänismaa
Browse more venture capital transactions:
Prev: 8/22/2024: Depot Technologies venture capital transaction
Next: 8/22/2024: Fanton venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. All VC database entries on this site are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs